NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI LO (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Viatris (2) is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ]. First approved in 2018.
Drug data last refreshed 39m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI LO is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for oral treatment of HIV-1 infection. The three-drug combination delivers complementary antiviral mechanisms in a single tablet to simplify patient adherence. It is indicated for HIV-1 treatment in antiretroviral-naive or experienced patients.
$0.135BPart D
PeakProduct is at peak commercial maturity with modest Part D utilization; team focus likely on market maintenance and operational efficiency rather than aggressive growth initiatives.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYMFI LO currently shows zero linked job postings, reflecting its mature market status and stable team structure at sponsor Viatris. Roles on this product emphasize commercial execution and market maintenance over innovation or expansion.
Brand ManagerProduct Manager
Worked on SYMFI LO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.